Close

SF3A1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This gene encodes a subunit of the splicing factor 3a protein complex. The splicing factor 3a heterotrimer is a component of the mature U2 small nuclear ribonucleoprotein particle (snRNP). U2 small nuclear ribonucleoproteins play a critical role in spliceosome assembly and pre-mRNA splicing.
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-CQ2281 Anti-SF3A1 (CBXS-3879) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-3879 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2282 Anti-SF3A1 (CBXS-4441) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-4441 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2283 Anti-SF3A1 (CBXS-4894) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-4894 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2284 Anti-SF3A1 (CBXS-5266) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-5266 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2285 Anti-SF3A1 (CBXS-5290) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-5290 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2286 Anti-SF3A1 (CBXS-0966) h(41BB-CD3ζ) CAR, pCDCAR1 Human, Rat, Mouse CBXS-0966 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2287 Anti-SF3A1 (CBXS-1576) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-1576 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ2288 Anti-SF3A1 (CBXS-1577) h(41BB-CD3ζ) CAR, pCDCAR1 Human CBXS-1577 Rabbit scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5705 Anti-SF3A1 (CBXS-3879) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-3879 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5706 Anti-SF3A1 (CBXS-4441) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-4441 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5707 Anti-SF3A1 (CBXS-4894) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-4894 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5708 Anti-SF3A1 (CBXS-5266) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-5266 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5709 Anti-SF3A1 (CBXS-5290) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-5290 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5710 Anti-SF3A1 (CBXS-0966) h(CD28-CD3ζ) CAR, pCDCAR1 Human, Rat, Mouse CBXS-0966 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5711 Anti-SF3A1 (CBXS-1576) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-1576 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-CQ5712 Anti-SF3A1 (CBXS-1577) h(CD28-CD3ζ) CAR, pCDCAR1 Human CBXS-1577 Rabbit scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.